

AGENDA

Sixth WFH Global Forum on the safety and supply of treatment products for bleeding disorders Making the Case for Clotting Factor Concentrates September 24-25, 2009

	Session	Speakers
Day one: Sept. 24	Trends in Supply & Usage	
8:30-8:45	Welcome	
SESSION 1 8:45-9:30	Factor usage – global data (15 minutes for questions and discussion) CHAIR Alok Srivastava	Jeff Stonebraker
9:30-10:15	Projected trends in supply and demand (15 minutes for questions and discussion) CHAIR Alok Srivastava	Patrick Robert
	Break	
SESSION 2 11:00-12:30	Prophylaxis models (30 minutes for discussion) CHAIR Alison Street	Kathelijn Fischer Victor Blanchette Alok Srivastava
12:30-2:00	Lunch	
SESSION 3 2:00-3:00	Economics and outcome assessments – threats to care in a tightening economy? (15 minutes for discussion) CHAIR Brian O'Mahony	Adam Hutchings Michael Lauer
3:00-3:30	Break	
SESSION 4 3:30-4:30	A streamlined regulatory pathway for biologics – Is it good or bad for the Bleeding Disorders Community? What are the risks and potential benefits? CHAIR Mark Skinner	Diane Dorman Jay Greissing Johanna Gray
4:30-5:00	Day one closing discussion	
	Dinner	
Day two: Sept. 25	Safety Issues and innovation	
SESSION 5 8:30-10:30	Inhibitors studies followed by roundtable discussion CHAIR Mike Soucie	Mike Makris Elena Santagostino Deborah Brown
	Break	
SESSION 6 11:00-12:30	variant Creutzfeldt Jakob Disease vCJD transmission, testing, risk assessments (15 minutes for discussion) CHAIR David Page	Albert Farrugia George Adams Bruce Evatt Chris James Bruce Ritchie
12:30-1:30	Lunch	
SESSION 7 1:30-2:30	Innovations and updates CHAIR Paula Bolton-Maggs	Novo Nordisk Dorthe Viuff Biogen Glenn Pierce Ipsen Jeffrey Lawrence BPL Clive Dash CSL Behring Lutz Bonacker
2:30-3:00	Closing discussion CHAIR Mark Skinner	